Amneal Pharmaceuticals, Inc. Class A Common Stock — Rendiconto Finanziario Trimestrale (NASDAQ:AMRX)

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 4.1272 B
Employee 8 500
Founded 2002
CEO Chintu PatelChirag Patel
Website www.amneal.com
Headquarter N/A
FIGI BBG00462PGG0
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

4.13 B Capitalizzazione di mercato

Rapporto prezzo/utili

57.27

Rapporto prezzo/fatturato

1.36

Amneal Pharmaceuticals Inc - Class A

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

AMRX

Financials

Amneal Pharmaceuticals Inc - Class A

Notizie

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing

Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term

Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX)

Amneal alla conferenza Barclays: crescita strategica e innovazione

Amneal at Barclays Conference: Strategic Growth and Innovation

New Strong Buy Stocks for March 9th

Best Value Stocks to Buy for March 9th

Truist alza il target su Amneal Pharmaceuticals per focus sui margini

Truist raises Amneal Pharmaceuticals stock price target on margin focus

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript